Dysregulated Expression of miRNAs in Immune Thrombocytopenia
Abdollah JafarzadehDepartment of Immunology, School of Medicine, Kerman University of Medical Sciences, 76169-13555, Kerman, IranHavva MarzbanDepartment of Pathology & Experimental Animals, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), 31975/148 Karaj, IranMaryam NematiDepartment of Hematology & Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, 76169-13555, Kerman, IranSara JafarzadehStudent Research Committee, School of Medicine, Kerman University of Medical Sciences, 76169-13555, Kerman, IranMaryam Mahjoubin‐TehranDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, 13131-99137, Mashhad, IranMichael R. HamblinLaser Research Centre, Faculty of Health Science, University of Johannesburg, 2028 Doornfontein, South AfricaHamed MirzaeiDepartment of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, 14176-13151, Tehran, IranHamid Reza MirzaeiDepartment of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, 14176-13151, Tehran, Iran
2021en
ABI
Abstract
In recent years the critical role of miRNAs has been established in many diseases, including autoimmune disorders. Immune thrombocytopenia purpura (ITP) is a predominant autoimmune disease, in which aberrant expression of miRNAs has been observed, suggesting that miRNAs are involved in its development. miRNAs could induce an imbalance in the T helper (Th)1/Th2 cell and Th17/Treg cell-related responses. Moreover, they could also cause alterations in Th9 and Th22 cell responses, and activate Tfh (T follicular helper) cell-dependent auto-reactive B cells, thus influencing megakaryogenesis. Herein, we summarize the role of immune-related miRNAs in ITP pathogenesis, and look forward to clinical applications.
Identifiers
Citations and references
Cited by 30 references